Literature DB >> 8764006

Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.

X Li1, Y Quan, E J Arts, Z Li, B D Preston, H de Rocquigny, B P Roques, J L Darlix, L Kleiman, M A Parniak, M A Wainberg.   

Abstract

Retroviral reverse transcription starts near the 5' end of unspliced viral RNA at a sequence called the primer binding site (PBS), where the tRNA primer anneals to the RNA template for initiation of DNA synthesis. We have investigated the roles of NCp7 in annealing of primer tRNA(Lys3) to the PBS and in reverse transcriptase (RT) activity, using a cell-free reverse transcription reaction mixture consisting of various 5' viral RNA templates, natural primer tRNA(Lys3) or synthetic primer, human immunodeficiency virus type I (HIV-1) nucleocapsid protein (NCp7), and HIV-1 RT. In the presence of tRNA(Lys3), NCp7 was found to stimulate synthesis of minus-strand strong-stop DNA [(-)ssDNA], consistent with previous reports. However, specific DNA synthesis was observed only at a NCp7/RNA ratio similar to that predicted to be present in virions. Moreover, at these concentrations, NCp7 inhibited the synthesis of nonspecific reverse-transcribed DNA products, which are initiated because of self-priming by RNA templates. In contrast to results obtained with tRNA(Lys3) as primer, NCp7 inhibited the synthesis of (-)ssDNA products primed by an 18-nucleotide (nt) ribonucleotide (rPR), complementary to the PBS, even though rPR can initiate synthesis of such material in the absence of preannealing with NCp7. Primer placement band shift assays showed that NCp7 was necessary for efficient formation of the tRNA-RNA complex. In contrast, NCp7 was found to prevent formation of the rPR-RNA complex. Since NCp7 appears to exert opposite effects (annealing versus dissociation) on tRNA(Lys3) and rPR substrates, the non-PBS binding regions of the tRNA(Lys3) molecule may play a role in the annealing of tRNA to the template. We also investigated the roles of an A-rich loop upstream of the PBS, a 7-nt region immediately downstream of the PBS, and a 54-nt deletion further downstream of the PBS in interactions with tRNA(Lys3). We found that deletions in the 54-nt region that may prevent formation of the U5-leader stem prevented tRNA(Lys3) placement and priming, while deletions in the A-rich loop or the 7-nt sequence had relatively minor effects in this regard.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764006      PMCID: PMC190453     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation.

Authors:  H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

2.  Nuclease footprinting of human immunodeficiency virus reverse transcriptase/tRNA(Lys-3) complexes.

Authors:  B M Wöhrl; B Ehresmann; G Keith; S F Le Grice
Journal:  J Biol Chem       Date:  1993-06-25       Impact factor: 5.157

3.  Analysis of the interactions of HIV1 replication primer tRNA(Lys,3) with nucleocapsid protein and reverse transcriptase.

Authors:  C Barat; O Schatz; S Le Grice; J L Darlix
Journal:  J Mol Biol       Date:  1993-05-20       Impact factor: 5.469

Review 4.  Priming of HIV replication by tRNA(Lys3): role of reverse transcriptase.

Authors:  S Litvak; L Sarih-Cottin; M Fournier; M Andreola; L Tarrago-Litvak
Journal:  Trends Biochem Sci       Date:  1994-03       Impact factor: 13.807

5.  A specific orientation of RNA secondary structures is required for initiation of reverse transcription.

Authors:  A Aiyar; Z Ge; J Leis
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro.

Authors:  G J Klarmann; C A Schauber; B D Preston
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

7.  Secondary structure of the HIV-2 leader RNA comprising the tRNA-primer binding site.

Authors:  B Berkhout; I Schoneveld
Journal:  Nucleic Acids Res       Date:  1993-03-11       Impact factor: 16.971

8.  Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.

Authors:  E J Arts; X Li; Z Gu; L Kleiman; M A Parniak; M A Wainberg
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

9.  Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome.

Authors:  B Allain; M Lapadat-Tapolsky; C Berlioz; J L Darlix
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

10.  An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis.

Authors:  D Herschlag; M Khosla; Z Tsuchihashi; R L Karpel
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  53 in total

1.  In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription.

Authors:  F Brulé; G Bec; G Keith; S F Le Grice; B P Roques; B Ehresmann; C Ehresmann; R Marquet
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions.

Authors:  M Hsu; L Rong; H de Rocquigny; B P Roques; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

3.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Authors:  S Druillennec; C Z Dong; S Escaich; N Gresh; A Bousseau; B P Roques; M C Fournié-Zaluski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Subtle alterations of the native zinc finger structures have dramatic effects on the nucleic acid chaperone activity of human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  Jianhui Guo; Tiyun Wu; Bradley F Kane; Donald G Johnson; Louis E Henderson; Robert J Gorelick; Judith G Levin
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Mechanism for nucleic acid chaperone activity of HIV-1 nucleocapsid protein revealed by single molecule stretching.

Authors:  M C Williams; I Rouzina; J R Wenner; R J Gorelick; K Musier-Forsyth; V A Bloomfield
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

7.  The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity.

Authors:  C Liang; X Li; L Rong; P Inouye; Y Quan; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

8.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro.

Authors:  Cécile Fournier; Jean-Claude Cortay; Caroline Carbonnelle; Chantal Ehresmann; Roland Marquet; Pierre Boulanger
Journal:  Virus Genes       Date:  2002-12       Impact factor: 2.332

Review 10.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.